Anita H. Clayton, MD

The GABA Pathway and New Clinical Trial Data in MDD and PPD

March 16, 2023

Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.

Kristina M. Deligiannidis, Anita H. Clayton

Original Research

Effect of Zuranolone vs Placebo in MDD

February 20, 2023

This phase 3 RCT found significant improvement in depressive symptoms with zuranolone beginning at day 3 of treatment.

Anita H. Clayton, Robert Lasser, Indrani Nandy, et al

Original Research

Lurasidone and Sexual Function

August 7, 2018

As you probably know, sexual dysfunction is a common side effect of antidepressants and antipsychotics. This secondary analysis of an RCT examines whether the atypical antipsychotic lurasidone was linked...

Anita H. Clayton, Joyce Tsai, Yongcai Mao, et al

Original Research

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

October 28, 2014

Anita H. Clayton, Karen A. Tourian, Kristen Focht, et al

Article

Prevalence of Substance Misuse in New Patients in an Outpatient Psychiatry Clinic Using a Prescription Monitoring Program

January 2, 2014

The purpose of this study was to investigate the value of a prescription monitoring program in identifying prescription drug misuse among patients presenting to a resident physicians' outpatient psychiatry...

Elle M. Sowa, Jonathan C. Fellers, Rachna S. Raisinghani, et al

Article

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

October 15, 2013

Anita H. Clayton, Susan G. Kornstein, Boadie W. Dunlop, et al

Educational Activity

Understanding Antidepressant Mechanism of Action and Its Effect on Efficacy and Safety

March 15, 2012

Anita H. Clayton

Article

Depression or Menopause? Presentation and Management of Major Depressive Disorder in Perimenopausal and Postmenopausal Women

February 18, 2010

In this review article, examine the risk of depression onset in perimenopausal and postmenopausal women and find out how to screen for and manage depression in your perimenopausal and...

Anita H. Clayton, Philip T. Ninan

Article

Distressing Sexual Problems in United States Women Revisited: Prevalence After Accounting for Depression

December 15, 2009

Catherine B. Johannes, Anita H. Clayton, Dawn M. Odom, et al

Letter to the Editor

Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents

December 14, 2007

Atma R. Yarlagadda, Anita B. Brown, Anita H. Clayton

Original Research

Symptoms of Sexual Dysfunction in Patients Treated for Major Depressive Disorder: A Meta-Analysis Comparing Selegiline Transdermal System and Placebo Using a Patient-Rated Scale

December 14, 2007

Anita H. Clayton, Bryan J. Campbell, Antonella Favit, et al

Original Research

Assessing the Onset of Antidepressant-Induced Sexual Dysfunction Using Interactive Voice Response Technology

April 16, 2007

Judith A. Dunn, Renee Arakawa, John H. Greist, et al

The GABA Pathway and New Clinical Trial Data in MDD and PPD

Effect of Zuranolone vs Placebo in MDD

Lurasidone and Sexual Function

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

Prevalence of Substance Misuse in New Patients in an Outpatient Psychiatry Clinic Using a Prescription Monitoring Program

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

Understanding Antidepressant Mechanism of Action and Its Effect on Efficacy and Safety

Depression or Menopause? Presentation and Management of Major Depressive Disorder in Perimenopausal and Postmenopausal Women

Distressing Sexual Problems in United States Women Revisited: Prevalence After Accounting for Depression

Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents

Symptoms of Sexual Dysfunction in Patients Treated for Major Depressive Disorder: A Meta-Analysis Comparing Selegiline Transdermal System and Placebo Using a Patient-Rated Scale

Assessing the Onset of Antidepressant-Induced Sexual Dysfunction Using Interactive Voice Response Technology

ELSEWHERE:

FOLLOW US:

Anita H. Clayton, MD

The GABA Pathway and New Clinical Trial Data in MDD and PPD

Effect of Zuranolone vs Placebo in MDD

Lurasidone and Sexual Function

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

Prevalence of Substance Misuse in New Patients in an Outpatient Psychiatry Clinic Using a Prescription Monitoring Program

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

Understanding Antidepressant Mechanism of Action and Its Effect on Efficacy and Safety

Depression or Menopause? Presentation and Management of Major Depressive Disorder in Perimenopausal and Postmenopausal Women

Distressing Sexual Problems in United States Women Revisited: Prevalence After Accounting for Depression

Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents

Symptoms of Sexual Dysfunction in Patients Treated for Major Depressive Disorder: A Meta-Analysis Comparing Selegiline Transdermal System and Placebo Using a Patient-Rated Scale

Assessing the Onset of Antidepressant-Induced Sexual Dysfunction Using Interactive Voice Response Technology

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles